

# Regional anesthesia in breast reconstructive surgery

<b>Submission date</b>	<b>Recruitment status</b>	<input type="checkbox"/> Prospectively registered
28/11/2024	No longer recruiting	<input type="checkbox"/> Protocol
<b>Registration date</b>	<b>Overall study status</b>	<input type="checkbox"/> Statistical analysis plan
28/01/2025	Completed	<input checked="" type="checkbox"/> Results
<b>Last Edited</b>	<b>Condition category</b>	<input type="checkbox"/> Individual participant data
02/02/2026	Cancer	

## Plain English summary of protocol

### Background and study aims

This study aims to find out if using regional anesthesia during breast reconstruction surgery can lower pain levels, reduce the need for painkillers and opioids, decrease complications after surgery, and shorten hospital stays.

### Who can participate?

Women aged 18 to 90 years who are scheduled for radical breast surgery (such as Skin-Sparing Mastectomy or Nipple-Sparing Mastectomy) or standard mastectomy (Modified Radical Mastectomy) with primary reconstruction using a prosthesis or expander placed beneath the pectoral muscle.

### What does the study involve?

Participants will be randomly assigned to one of two groups. One group will receive the standard general anesthesia, while the other group will receive regional anesthesia. Both groups will complete a pain questionnaire before surgery and at 6 and 24 hours after surgery. The study will also record the use of painkillers and opioids, any complications within 24 hours after surgery, and the length of hospital stay.

### What are the possible benefits and risks of participating?

Participants who receive regional anesthesia may experience lower pain levels after surgery. There are no additional risks compared to the usual procedure.

### Where is the study run from?

University Hospital Dubrava/Klinička Bolnica Dubrava (Croatia)

### When is the study starting and how long is it expected to run for?

October 2021 to June 2024

### Who is funding the study?

University Hospital Dubrava/Klinička Bolnica Dubrava (Croatia)

Who is the main contact?  
Domagoj Eljuga, deljuga@gmail.com

## Contact information

### Type(s)

Principal investigator

### Contact name

Dr Domagoj Eljuga

### ORCID ID

<https://orcid.org/0000-0001-8902-0072>

### Contact details

Maksimirска cesta 88  
Zagreb  
Croatia  
10000  
+385 91 383 99 50  
deljuga@gmail.com

### Type(s)

Public

### Contact name

Dr Krešimir Martic

### ORCID ID

<https://orcid.org/0009-0002-6025-4806>

### Contact details

Nova cesta 136A  
Zagreb  
Croatia  
10000  
+38598 752178  
kmartic76@gmail.com

### Type(s)

Scientific

### Contact name

Dr Ivo Jurisic

### ORCID ID

<https://orcid.org/0000-0002-1755-0039>

### Contact details

Ogulinska 4a  
Zagreb  
Croatia  
10000  
+385 98 9050015  
ivojurisic1@gmail.com

## Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

### ClinicalTrials.gov (NCT)

Nil known

### Protocol serial number

Nil known

## Study information

### Scientific Title

Regional anesthesia in breast reconstructive surgery

### Study objectives

Regional anesthesia in breast reconstructive surgery is associated with lower pain score, lower opioid usage, lower complication rate and shorter hospital stay.

### Ethics approval required

Ethics approval required

### Ethics approval(s)

approved 22/02/2022, Ethics committee of Clinical Hospital Dubrava (Avenija Gojka Suska 6, Zagreb, 10000, Croatia; +385 1 290 2726; povjerenstvo.eticko@kbd.hr), ref: 2022/2701 04

### Study design

Interventional randomized controlled trial

### Primary study design

Interventional

### Study type(s)

Treatment

### Health condition(s) or problem(s) studied

Breast cancer

### Interventions

Patients will be randomly assigned to one of two groups via blinded selection.

1. First group: Patients will undergo the standard anesthetic protocol used for general anesthesia.

2. Second group: Patients will receive regional anesthesia following this protocol:

- o Thoracic paravertebral block with 0.3 mL/kg of ideal body weight of 0.5% levobupivacaine + 4 mg dexamethasone + epinephrine (1:200,000), followed by:
- o Additional pectoral block comprising:  
0.2 mL/kg of ideal body weight of 0.5% levobupivacaine + 4 mg dexamethasone + epinephrine (1:200,000) administered between the pectoralis major and pectoralis minor muscles.  
A supplementary block between the pectoralis minor and serratus anterior muscles with 0.2 mL/kg of ideal body weight of 0.5% levobupivacaine + 2 mg dexamethasone + epinephrine (1:200,000).

For premedication, Dormicum (Midazolam) 3–5 mg intramuscularly will be administered 30 minutes before the block (administered in the ward). During block administration, 1–3 mg Dormicum will be given intravenously. During surgery, deep sedation will be achieved with Propofol at a dose of 30–70 mcg/kg per minute, along with oxygen via mask at 12 L/min.

## **Intervention Type**

Drug

## **Phase**

Not Applicable

## **Drug/device/biological/vaccine name(s)**

levobupivacaine, dexamethasone, epinephrine, Dormicum (midazolam), propofol

## **Primary outcome(s)**

Pain is measured using a visual analogue scale at baseline, 6 and 24h

## **Key secondary outcome(s)**

Measured using patient records after hospital stay:

1. Opioid consumption
2. Duration of hospital stay

## **Completion date**

30/06/2024

## **Eligibility**

### **Key inclusion criteria**

Women aged 18–90 years scheduled for radical breast surgery (Skin-Sparing Mastectomy (SSM) or Nipple-Sparing Mastectomy (NSM)) or standard mastectomy (Modified Radical Mastectomy (MRM)) with primary reconstruction using a prosthesis or expander placed beneath the pectoral muscle

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Mixed

**Lower age limit**

18 years

**Upper age limit**

90 years

**Sex**

Female

**Total final enrolment**

50

**Key exclusion criteria**

Patients experiencing chronic pain or those undergoing pain therapy will not be included in the study.

**Date of first enrolment**

01/02/2022

**Date of final enrolment**

31/12/2023

## Locations

**Countries of recruitment**

Croatia

**Study participating centre**

Clinical Hospital Dubrava

Avenija Gojka Suska 6

Zagreb

Croatia

10000

## Sponsor information

**Organisation**

University Hospital Dubrava

**ROR**

<https://ror.org/00mgfdc89>

# Funder(s)

## Funder type

Hospital/treatment centre

## Funder Name

Klinička Bolnica Dubrava

## Alternative Name(s)

Clinical Hospital Dubrava, KBD

## Funding Body Type

Private sector organisation

## Funding Body Subtype

Other non-profit organizations

## Location

Croatia

# Results and Publications

## Individual participant data (IPD) sharing plan

The datasets generated during the current study will be stored in a non-publicly available repository. All data about each individual patient is stored in paper and as well in electronic form in our Regional Anesthesia folder on our Department disk.

## IPD sharing plan summary

Stored in non-publicly available repository

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		01/06/2025	02/02/2026	Yes	No
<a href="#">Participant information sheet</a>			29/11/2024	No	Yes